2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Aggressive Lymphoma, Research, AML, MDS, MPN, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2537 Accumulation of patient- and disease-related pretransplant risk factors stratifies survival after allogeneic HCT in older adults with AML or MDS

Suravi Raychaudhuri, MD, Abigail L. Liang2, Ted Gooley, PhD3, Chris Davis4, Ryan Basom5, Mary-Elizabeth Percival, MD6, Mohamed Sorror, MD, MS7
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 University of Washington, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Introduction:

As an increasing number of patients in the seventh decade of life and beyond undergo allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), the optimal selection of candidates most likely to benefit from HCT remains an important question. Herein, we retrospectively analyzed outcomes of a large single-center cohort of older patients undergoing HCT. Our objective was to identify risk factors that stratify older patients with regard to overall survival (OS) and relapse-free survival (RFS).

 Methods:

We collected data from patients aged ≥ 60 years who received HCT between 2015-2022 for AML or MDS at Fred Hutchinson Cancer Center. Clinical variables were collected from the electronic medical record. Variables of interest included hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score, disease risk index (DRI), and measurable residual disease (MRD) prior to transplant. MRD was defined as abnormal karyotype, FISH, or flow cytometry assessed on the last bone marrow examination prior to HCT. Molecular testing for MRD was not included since testing was rarely available during the study time period. DRI was categorized as previously described (Armand, Blood, 2014). OS was measured from time of transplant to death. RFS was measured from time of transplant to relapse or death. Hazard ratios (HR) were calculated using multivariable Cox regression.

Results:

We identified 468 patients who underwent allogeneic HCT for AML (n=263, 56%) and MDS (205, 44%). Of these, 151 (32%) were aged 60–64 years, 193 (41%) were aged 65–69 years, and 124 (26%) were aged 70 years or older. 305 (65%) had intermediate DRI and 159 (34%) had high DRI. The remaining 4 patients had inadequate cytogenetic information at the time of diagnosis to determine disease risk. HCT-CI score was ≥ 3 for 199 (42%) of patients. 163 (35%) had myeloablative conditioning and 305 (65%) received reduced-intensity or non-myeloablative conditioning regimens. For the whole cohort, median OS was 35.6 months (95% CI 28.3-53.0) and median RFS was 24.5 months (95% CI 17.1-33.2). Median OS was 62.9 months (95% CI 28.2-not reached) for patients aged 60-64, 34.4 months (95% CI 21.9-42.8) for those aged 65-69, and 29.5 months (95% CI 16.4-41.7) for those aged 70 and above.

We examined several variables through multivariable Cox regression and identified age, high-risk disease, MRD by abnormal cytogenetics or flow cytometry prior to HCT, and HCT-CI as factors that had an impact on OS; conditioning intensity, CMV status, donor type, and donor sex showed minimal association with survival. For the purpose of identifying favorable and unfavorable groups, we dichotomized age at ≥ 65 years. A favorable group was identified and consisted of patients < 65, HCT-CI < 3, with intermediate-risk disease, and normal cytogenetics or flow prior to HCT (n=41, 9%). Conversely, the unfavorable group (n=427, 91%) consisted of patients ≥ 65, HCT-CI ≥ 3, high-risk disease, or abnormal cytogenetics or flow prior to HCT. The HR (favorable vs. unfavorable) for mortality was 0.30 (0.16-0.57, p<0.001). Median OS was not reached for the favorable group; median OS for the unfavorable group was 28.8 months (95% CI 24.0-38.5). Median RFS was not reached for the favorable group, while median RFS for the unfavorable group was 18.1 months (95% CI 12.8-26.9). Compared to the favorable risk group, accumulation of each additional risk factor (either age ≥ 65, HCT-CI ≥ 3, high-risk disease, or MRD prior to HCT) increased the HR for mortality. HR for mortality with one risk factor was 2.1 (95% CI 1.1-4.1), two risk factors was 3.7 (95% CI 2.0-7.2), three risk factors was 4.3 (95% CI 2.2-8.4), and four risk factors was 6.4 (95% CI 3.0-14.0).

Conclusion:

This retrospective analysis identified several key factors associated with worse OS and RFS in older HCT patients with AML or MDS. We identified an unfavorable group, defined as patients with at least one risk factor of age ≥ 65 years old, HCT-CI ≥ 3, high-risk disease, or MRD prior to HCT, had significantly lower OS and RFS. These patients could be candidates for clinical trials of novel AML-directed conditioning regimens, graft manipulation, or post-HCT maintenance. Conversely, the favorable group of patients who lack those risk factors should be considered for HCT, as they may have excellent post-HCT survival.

Suravi Raychaudhuri, MD: No relevant conflicts of interest to declare.